Endotracheal bleomycin administration in rats and other animal species causes rapid development of pulmonary fibrosis, characterized by increased lung collagen synthesis and deposition. To clarify the mechanism, lung fibroblasts from bleomycin-treated rats (BRF) were isolated and maintained in tissue culture. They were then compared with those from normal untreated control animals, with respect to several key parameters of collagen metabolism. BRF synthesized collagen at a rate 35-82% above normal rat lung fibroblasts (NRF). This difference did not appear to be due to the selection of a clone by the subculture process. Furthermore, analysis of newly synthesized collagen type composition, revealed a significantly lower ratio of type III to type I collagen. Noncollagenous protein synthesis, however, was not significantly different from normal. Collagenase production and growth rate were also unaffected. BRF, however, was morphologically indistinguishable from NRF, even at the ultrastructural level. Upon further bleomycin (1 microgram/ml) exposure in vitro, BRF could be further stimulated to synthesize collagen at 82% above the rate for untreated BRF. This is comparable to the 90% increase in NRF treated in vitro (compared with untreated NRF). These results would favor the conclusion that bleomycin induces pulmonary fibrosis, by causing directly and/or indirectly lung fibroblasts (or a certain line of lung fibroblasts) to synthesize collagen at a higher rate without any associated increase in growth rate. 
Introduction
Administration of the antitumor antibiotic bleomycin in humans and experimental animals, above certain cumulative doses, causes pneumonitis and pulmonary fibrosis (1, 2) . The association between pneumonitis and fibrosis would suggest some role for cells of the inflammatory and immune systems and their mediators in regulating the fibrogenic response. There is ample evidence to support such a possibility in both bleomycin-induced, as well as, other forms of pulmonary fibrosis (3) (4) (5) (6) . A second possibility that products of alveolar epithelial, endothelial, and other cellular injury (as induced by bleomycin) are responsible for the accumulation of connective tissue has not been investigated. Finally, the fibrogenic response could also be the result of direct bleomycin stimulation of the lung connective tissue cells.
The ability of bleomycin to induce increased fibroblast net collagen synthesis in vitro has been demonstrated (7, 8) . Further analysis reveals that most of the increased synthesis is in type I procollagen, resulting in a decreased ratio of newly synthesized type III to type I collagen (7) . Polysomes from these bleomycin-treated cells synthesized more collagen than those from untreated control cells (8) . Prolylhydroxylase activity is also increased, and is accompanied by increased rates of newly synthesized collagen degradation, as measured by quantitation of free and peptide-bound radioactive hydroxyproline (8) . Other investigators have also reported that in vivo bleomycin treatment causes decreased collagenolytic activity in mouse skin (9) and rat lungs (10) .
In this paper, the effect of in vivo bleomycin treatment on isolated rat lung fibroblasts was examined and compared with in vitro treatment. The data reveal some similarities, and suggest that bleomycin can cause pulmonary fibrosis, at least partially, by stimulation of lung fibroblast collagen synthesis due possibly to irreversible effects of certain cellular mediators.
Methods
Reagents. Outdated bleomycin (Blenoxane) was a generous gift of Bristol Laboratories Div., Bristol-Myers Co. (Syracuse, NY). L- [2,3,4,5- 3H]Proline (>100 Ci/mmol), [methyl-3Hlthymidine (6.7 Ci/mmol), and [methyl-"4C]methylated collagen (2-20 uCi/mg) were obtained from New England Nuclear (Boston, MA). Dulbecco's modified Eagle's medium (DME),' penicillin-streptomycin-fungizone stock solution, and fetal calf serum were purchased from Gibco Laboratories pulse, the cells were harvested using 0.25% trypsin and transferred to glass fiber filters using an automatic cell harvester (Bellco Glass, Inc., Vineland, NJ). After they were washed with cold 5% trichloracetic acid (TCA) and distilled H20, the filters were dried, placed in vials, and counted in a scintillation counter (model LS7000; Beckman Instruments, Inc., Fullerton, CA). The results were expressed as disintegrations per minute incorporated per 6 h/well.
Actual growth curves were also obtained to measure proliferation. Fibroblasts were plated onto 35-mm diameter tissue culture dishes in DME supplemented with 10% fetal calf serum (Costar, Data Packaging Corp.). At daily intervals, up to 5 d after plating, the dishes were trypsinized (0.25% trypsin) to detach the cells, which were placed in hemocytometers for actual cell counting using the microscope. Results were expressed as cell number per dish.
Collagen production. Collagen synthesis (net production) assays were performed using only fully confluent cells in 35-mm diameter tissue culture dishes. Spent media were removed and the monolayer was washed twice gently using DME (prewarmed to 370C). Cells to be treated with bleomycin in vitro were then incubated for 24 h in DME containing the desired concentration of drug. Cells were then pulsed by replacing the media with fresh DME supplemented with 50 Mg/ml sodium ascorbate, 80 Mg/ml fl-aminopropionitrile, and 10 MUCi/ml [3Hjproline. After a 6-h incubation with 5% CO2 and at 370C, the media and one wash (1.0 ml of PBS) were separated from the cell layer. The latter was scraped using a rubber policeman and resuspended in 2.0 ml PBS. Both media (after supplementation with 0.2 mg/ml with bovine serum albumin) and cell layer samples were then made up to 10% in TCA using a 50% stock solution. The pellets after centrifugation were washed twice with cold 10% TCA and finally resuspended in 500 Ml 0.1 N NaOH. After a 10-min incubation at 370C, the suspension was neutralized to pH 7.3-7.5 with 1.0 N HCG after addition of 250 Ml of 1.0 M Tris HCI, pH 7.5. The final volume was then made up to 1.0 ml using distilled H20. A 100-Mil aliquot of the cell layer was then taken for protein determination. The samples were then supplemented with (in final concentrations) 5 mM Nethylmaleimide, 10 mM benzamidine, 0.2 mM phenylmethylsulfonylfluoride (PMSF), and 5 mM CaC12. 500-Ml samples were then digested for 2 h at 37°C with 35 ug of bacterial collagenase, previously purified by gel filtration on Sephacryl S-200 resin (10, 11) . Previous data (10) and other control studies (not shown) have demonstrated that no more radioactivity was digested beyond 60-90 min of incubation. The digests were then processed exactly as described previously (10), which is a minor modification of the method of Peterkovsky and Diegelmann (1 1 (14) . At the end of the run, and upon fixing, staining, impregnating with EN3HANCE, and drying, the gels were exposed to XAR-5 film for 2-5 d before development using a standard commercial X-ray film developer. The autoradiograms were then scanned and bands quantitated using a Zeineh laser densitometer (LKB Instruments, Gaithersburg, MD) equipped with an integrator. Collagenase assay. Collagenase production and/or release were measured by assaying the conditioned media of the cultured lung fibroblasts for total (i.e., latent plus active) collagenase activity. Media from seven T-25 flasks were pooled and concentrated 10-15-fold using an Amicon device and a UMIO membrane (Amicon Corp., Scientific Sys. Div., Danvers, MA) at 4VC. Since latent activity was very low, only total activity was determined by predigesting the concentrated conditioned media with 10 Mg/ml of trypsin for 15 min at 370C. The trypsin was then inactivated with 40 jg/ml of soybean trypsin inhibitor. 160-Ml aliquots of the concentrated media were then incubated with 100 Ml of substrate solution containing 0.2 MuCi/ml of '4C-methylated acid soluble calf skin collagen, 10 Mg/ml cold acid soluble calf skin collagen, 50 mM Tris HCI, pH 7.5, 0.2 M NaCl, 5 mM CaC12, 5 mM N-ethylmaleimide, 10 mM benzamidine, and 0.2 mM PMSF. After an 18-h incubation at 25°C, 100 Ml of a solution containing 60 mM Tris HCI, pH 6.8, 3% SDS, 20% glycerol, and 10% mercaptoethanol was added and the samples were heated in a boiling water bath for 2 min. 100 ul was then subjected to SDS-PAGE as described above and the radioactive bands were quantitated by integration of a densitometric scan of the autoradiogram. Results were expressed as percentage of total radioactivity (in all bands) in the TCA and TCB bands.
Results
Fibroblast isolation. Addition of collagenase to lung mince did not improve the yield of fibroblasts significantly, and thus collagenase was omitted. Lung tissue from bleomycin-treated animals was more efficiently digested than normal lungs. Thus less incubation time was required for bleomycin lungs to achieve the same cellular yield as from control lungs. This is probably the result of increased cellularity in bleomycin lungs due to influx of inflammatory cells and increased connective tissue cells. No morphologic differences were apparent between NRF and BRF, using both phase-contrast light microscopy and electron microscopy. Electron Elongated projections representative of anchoring strands were also present. Although fine fibrillar structures ( Fig. 1 B, inset) were present in the cytosol (of both NRF and BRF), the more massive bundles of filament containing electron-dense areas, typical of myofibroblasts (17), were not seen. Thus from the morphologic standpoint, no differences were apparent between NRF and BRF. Growth rate. Increased connective tissue deposition may be a result of increased fibroblast metabolic activity and/or proliferation. Using the fibroblast isolation procedure as described above, and in vitro measurements of cell growth, no detectable difference was noted between NRF and BRF growth rates (Fig. 2) . Using cell-counting techniques, a doubling time of just under 2 d was obtained for both NRF and BRF. DNA synthetic rates were also unchanged as a result of in vivo bleomycin treatment. NRF incorporated 6,750±271 (SEM) dpm/well (n = 6), and BRF incorporated 6,393±300 (SEM) dpm/well (n = 6) of [3H]methylthymidine in 6 h of incubation.
These data suggest that bleomycin treatment in vivo caused no significant change in lung fibroblast growth rates, at least after isolation for in vitro measurements. Doubling times as well as DNA synthetic rates were also unchanged as a function of the number of passages the cells underwent (Table I ). This implies that at least according to this parameter of cell function, no clonal selection took place to account for the observed differences (in collagen production) in later passages.
Collagen production. Bleomycin-induced pulmonary fibrosis is characterized by increased lung collagen accumulation (13) . Other investigators have also reported on the ability of bleomycin to directly stimulate fibroblast collagen production in vitro (7, 8) . Similar results were obtained from BRF. Table II shows the results of a typical experiment with BRF synthesizing collagen and secreting into the media at a rate 52% above that of NRF, with the difference being statistically significant at P < 0.025. In the cell layer, BRF synthesized collagenous proteins at 60% above the rate for NRF, the difference being also statistically significant at P < 0.02. Noncollagenous protein synthetic rates, however, were unaffected in the media layer, but were elevated by 47% (P < 0.05) in the cell layer. Although the percent increase above NRF was variable from one BRF preparation to another, every preparation tested demonstrated a statistically significant increase, with a range of 35-82% above the rate for NRF. Additionally this increased synthesis was specific for collagenous protein, especially in terms of secreted proteins. The basis for this variability is uncertain but may be related to the variability in response to the outdated bleomycin. There is no relationship between the initial number of fibroblasts adapting to culture and the observed increased collagen production.
Expression of synthetic rates on a per 105 cell basis gave similar results, since the protein/cell ratio did not differ significantly between NRF and BRF. Determination of synthesis by measurement of radioactive hydroxyproline (12, 13) also yielded similar results (data not shown). The possibility that the rate of proline incorporation may be altered by changes in the intracellular pools was investigated by measuring total free proline in both BRF and NRF. This was done on cells grown to confluence and incubated 6 h in fresh serum-free medium just before assay. The results show NRF to contain 38.03±1.93 (SEM, n = 4) nmol free proline/mg protein vs. 35.07±2.11 (SEM, n = 4) nmol/mg protein in BRF. The difference was not statistically significant, thus making it unlikely that any difference in rates of proline incorporation was due to changes in total proline pool size. To ascertain that this increase in collagen production by BRF was not due to selection of a more active clone by the passaging process, experiments were undertaken to examine the effect of passaging on the observed differences in this parameter. Table III revealed that increased collagen production was relatively invariant as a function of passage number (from the primary to tenth passage). The results again suggest that the observed difference between NRF and BRF is not due to clonal selection by the process of subculture.
Type III/type I ratios. Fibrotic lesions are known to contain lesser amounts of type III collagen relative to type I collagen (18) (19) (20) , except in the early stages of wound healing (21). Bleomycin treatment, in vivo causes a similar decrease in the relative type III collagen content of lungs (22) . In vitro treatment of isolated fibroblasts by this drug also results in a reduction in this ratio (type III vs. type I) in the newly synthesized procollagens (7). Figs. 3 and 4 , and Table IV show that BRF also synthesized collagens with a lower type III/ 1000 .
-BRF l type I collagen ratio. Analysis by anion-exchange chromatography revealed BRF to synthesize only 60% of the relative content of type III procollagen synthesized by NRF (Fig. 3) . Analysis by SDS-PAGE revealed a comparable reduction of 58.4% by BRF relative to NRF (Fig. 4) . These differences between NRF and BRF values were statistically significant at P < 0.05.
Collagenase production. Previous studies using a cutaneous model of bleomycin-induced fibrosis revealed a reduction in skin collagenase activity (9) . Such a reduction in collagen catabolism has been suggested as a contributor to the fibrotic end result (10) . Although there is also an overall reduction in total lung collagenolytic activity after bleomycin treatment (10) , BRF-conditioned media revealed similar levels of total collagenase activity as NRF media (17.6±1.9% digestion for BRF vs. 18.7±1.3% for NRF; values were mean±SEM, n = 4). Thus, increased collagen synthesis in BRF cannot be attributed to decreased collagenase secretion and activity.
Effects of in vitro bleomycin. In vitro bleomycin treatment The results show that BRF produced collagen at a significantly higher rate than NRF, unaccompanied by any alteration in growth rate. The lack of significant difference in growth rate is in contrast to a recent study (24) using a similar model but different time points (7-8 d after bleomycin instillation vs. 14 d in this study) and method for lung fibroblast isolation (outgrowths from lung explants vs. trypsin digestion in this study). The discrepancy may be the result of one or both of these two factors. However, in their system, isolation using proteases also yielded the same result (Absher, M., J. Hildebran, L. Trombley, J. Woodcock-Mitchell, and J. Marsch, unpublished observations) (24) , thus suggesting that the difference in time of isolation after bleomycin instillation may be the critical factor. This possibility is consistent with the following scenano. Initial direct bleomycin toxicity impairs the growth and proliferation of lung cells, including fibroblasts. Recovery from Despite this apparent lack of difference in growth rates in this study, lungs from bleomycin-treated animals, however, are digested more efficiently and to a greater extent, resulting in a higher initial yield of cells, than those from control animals. This is probably a reflection of the increased cellularity of bleomycin lungs secondary to inflammation and increased connective tissue cell numbers. The newly synthesized collagen also contained a lower relative content of type III vs. type I collagen, consistent with the composition of fibrotic lesions (19, 20, 22) and of normal isolated fibroblasts treated with bleomycin in vitro (7) . Collagenase and protease (data not shown) production and secretion were also unaffected by in vivo bleomycin treatment.
The mechanism of this alteration in lung fibroblast collagen production can only be speculated upon at this time. The simplistic approach would be to regard this as the result of direct bleomycin effects on the lung fibroblasts in vivo, mimicking the well-described in vitro effects of this drug on isolated fibroblasts (7, 8) . However this appears unlikely for the following reasons: 1) very little bleomycin is in the lung 7-14 d after treatment (25), and in one study < 25% of peak levels remained in the lung 24 h after treatment (26) . BRF was isolated 14 d after treatment, thus very little bleomycin should remain during the isolation procedure. 2) Furthermore, BRF could be further stimulated by in vitro bieomycin treatment to an extent equal to that of NRF, suggesting that BRF have retained the responsiveness of normal fibroblasts to this drug. In in vitro studies we have found that rechallenge with bleomycin is toxic to fibroblasts and severely impairs their growth rate (data not shown). BRF, on the other hand, showed none of these effects (i.e., it propagated and subcultured normally). Thus there are distinct differences between cells treated with bleomycin in vitro and those derived from bleomycin-treated animals (i.e., BRF). These differences provide further support for the conclusion that increased collagen production by BRF is not due to direct bleomycin effects on lung fibroblasts in vivo (i.e., before their isolation).
Despite these observations, however, we cannot rule out an in vivo mediated but direct irreversible effect on these fibroblasts, resulting in homogeneous alteration of all cell populations or selection of a more active (in terms of collagen synthesis) subpopulation. The latter possibility is supported by data showing the heterogeneity of fibroblast populations (27) .
Alternative mechanisms would invoke indirect bleomycin effects, but ultimately should result in the saihe outcome as described in the two possible schemes outlined above. The irreversible alterations of BRF may be mediated by factors produced by cells of the immune system (e.g., alveolar macrophage and lymphocytes) upon stimulation by the bleomycininduced process. These cells are known to be sources of relatively well-defined mediators capable of regulating fibroblast growth and metabolism (28) (29) (30) . Furthermore, mediators produced by mononuclear cells can irreversibly alter certain fibroblast functions (31) . Finally, bleomycin effects on other cells (e.g., endothelial, epithelial, etc.) could also result in release of factors, with similar consequences on fibroblasts. Although these alterations appear irreversible under in vitro culture conditions, the bleomycin-induced increased rate of lung collagen synthesis in vivo, on the other hand, is finite (10, 13) . Since BRF was obtained at 14 d after bleomycin instillation, which is the period of increased lung collagen synthesis, it may be that inhibitory factors are required to down-regulate these BRF in vivo to return to the quiescent state seen at periods 2 8 wk after bleomycin instillation. This would imply that the irreversibility is applicable only to the in vitro status of these BRF.
